Blood levels of S-100 calcium-binding protein B, high- sensitivity C-reactive protein, and interleukin-6 for changes in depressive symptom severity after coronary artery bypass grafting: Prospective cohort nested within a randomized, controlled trial

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Pearlman, Daniel M ^a,b   Brown, Jeremiah R ^b,c   MacKenzie, Todd A ^b,c   Hernandez, Felix ^d   Najjar, Souhel ^a  

^a Neuroinflammation Research Group Epilepsy Center Division Department of Neurology   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d EASTERN MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; PROTEIN S100B; IL6 PROTEIN, HUMAN; S100B PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER DISRUPTION; BODY MASS; BODY WEIGHT; CELL ACTIVATION; CELL DAMAGE; CLINICAL ARTICLE; COHORT ANALYSIS; CORONARY ARTERY BYPASS GRAFT; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FEMALE; GLIA CELL; HUMAN; LIMIT OF DETECTION; MALE; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY BYPASS; DEPRESSION; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SEVERITY OF ILLNESS INDEX;

EID: 84908172716     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111110     Document Type: Article

References (104)

1. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O (2013) Neuroinflammation and psychiatric illness. J Neuroinflammation 10: 43.
2. Najjar S, Pearlman DM, Devinsky O, Najjar A, Zagzag D (2013) Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. J Neuroinflammation 10: 142.
3. Najjar S, Pearlman DM, Hirsch S, Friedman K, Strange J, et al. (2014) Brain biopsy findings link major depressive disorder to neuroinflammation, oxidative stress, and neurovascular dysfunction: a case report. Biol Psychiatry 75: e23-26.
4. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, et al. (2011) Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 8: 94.
5. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9: 46-56.
6. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with Creactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71: 171-186.
7. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, et al. (2005) Relation of Creactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 4: 371-380.
8. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, et al. (2010) A metaanalysis of cytokines in major depression. Biol Psychiatry 67: 446-457.
9. Hiles SA, Baker AL, de Malmanche T, Attia J (2012) Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med 42: 2015-2026.
10. Liu Y, Ho RC, Mak A (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 139: 230-239.
11. Ford DE, Erlinger TP (2004) Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 164: 1010-1014.
12. Hickman RJ, Khambaty T, Stewart JC (2014) C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004. J Behav Med 37: 621-629.
13. Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27: 24-31.
14. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, et al. (2008) Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 42: 151-157.
15. Miguel-Hidalgo JJ, Baucom C, Dilley G, Overholser JC, Meltzer HY, et al. (2000) Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 48: 861-873.
16. Altshuler LL, Abulseoud OA, Foland-Ross L, Bartzokis G, Chang S, et al. (2010) Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord 12: 541-549.
17. Webster MJ, O'Grady J, Kleinman JE, Weickert CS (2005) Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neurosci 133: 453-461.
18. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, et al. (2000) Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 5: 142-149.
19. Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, et al. (2013) Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 70: 812-820.
20. Kayser M (2014) Severe infection and autoimmune disease are associated with increased risk of mood disorders. Evid Based Ment Health 17: 20.
21. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, et al. (2003) Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 160: 1342-1345.
22. Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, et al. (2010) Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry 15: 535-547.
23. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, et al. (2005) Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 66: 41-48.
24. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, et al. (2005) Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 19: 23-27.
25. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, et al. (2009) Activation of central nervous system inflammatory pathways by interferonalpha: relationship to monoamines and depression. Biol Psychiatry 65: 296-303.
26. Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ (2002) Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol 147: 1142-1146.
27. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, et al. (2012) Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 73: 1128-1138.
28. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, et al. (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344: 961-966.
29. Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, et al. (2001) Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 158: 1252-1257.
30. Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, et al. (2007) Paroxetine for prevention of depressive symptoms induced by interferonalpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 25: 1163-1174.
31. Raison CL, Rye DB, Woolwine BJ, Vogt GJ, Bautista BM, et al. (2010) Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol Psychiatry 68: 942-949.
32. Martins JG (2009) EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 28: 525-542.
33. Bloch MH, Hannestad J (2012) Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 17: 1272-1282.
34. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY (2014) Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a metaanalysis. Prog Neuropsychopharmacol Biol Psychiatry 48: 79-85.
35. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, et al. (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11: 680-684.
36. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, et al. (2010) Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 68: 748-754.
37. Cremeans-Smith JK, Soehlen S, Greene K, Alexander T, Delahanty DL (2009) In-hospital levels of C-reactive protein and IL-6 predict post-operative depressive symptoms among patients undergoing total knee replacement surgery. Brain Behav Immun 23: 1096-1103.
38. Yang L, Wang J, Zhang L, Hou J, Yuan X, et al. (2012) Preoperative highsensitivity C-reactive protein predicts depression in patients undergoing coronary artery bypass surgery: a single-center prospective observational study. J Thorac Cardiovasc Surg 144: 500-505.
39. Poole L, Kidd T, Leigh E, Ronaldson A, Jahangiri M, et al. (2014) Depression, C-reactive protein and length of post-operative hospital stay in coronary artery bypass graft surgery patients. Brain Behav Immun 37: 115-121.
40. Newman MF, Mathew JP, Grocott HP, Mackensen GB, Monk T, et al. (2006) Central nervous system injury associated with cardiac surgery. Lancet 368: 694-703.
41. Miguel-Hidalgo JJ, Overholser JC, Jurjus GJ, Meltzer HY, Dieter L, et al. (2011) Vascular and extravascular immunoreactivity for intercellular adhesion molecule 1 in the orbitofrontal cortex of subjects with major depression: agedependent changes. J Affect Disord 132: 422-431.
42. Gudmundsson P, Skoog I, Waern M, Blennow K, Palsson S, et al. (2007) The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry 15: 832-838.
43. Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, et al. (2010) Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 44: 321-330.
44. Niklasson F, Agren H (1984) Brain energy metabolism and blood-brain barrier permeability in depressive patients: analyses of creatine, creatinine, urate, and albumin in CSF and blood. Biol Psychiatry 19: 1183-1206.
45. Lavoie KL, Pelletier R, Arsenault A, Dupuis J, Bacon SL (2010) Association between clinical depression and endothelial function measured by forearm hyperemic reactivity. Psychosom Med 72: 20-26.
46. Valkanova V, Ebmeier KP (2013) Vascular risk factors and depression in later life: a systematic review and meta-analysis. Biol Psychiatry 73: 406-413.
47. Serlin Y, Levy J, Shalev H (2011) Vascular pathology and blood-brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus. Cardiovasc Psychiatry Neurol 2011: 609202.
48. Permoda-Osip A, Dorszewska J, Skibinska M, Chlopocka-Wozniak M, Rybakowski JK (2013) Hyperhomocysteinemia in bipolar depression: clinical and biochemical correlates. Neuropsychobiology 68: 193-196.
49. Zill P, Baghai TC, Schule C, Born C, Frustuck C, et al. (2012) DNA methylation analysis of the angiotensin converting enzyme (ACE) gene in major depression. PLoS ONE 7: e40479.
50. Do DP, Dowd JB, Ranjit N, House JS, Kaplan GA (2010) Hopelessness, depression, and early markers of endothelial dysfunction in U.S. adults. Psychosom Med 72: 613-619.
51. Dimopoulos N, Piperi C, Salonicioti A, Mitsonis C, Liappas I, et al. (2006) Elevation of plasma concentration of adhesion molecules in late-life depression. Int J Geriatr Psychiatry 21: 965-971.
52. Schaefer M, Horn M, Schmidt F, Schmid-Wendtner MH, Volkenandt M, et al. (2004) Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain Behav Immun 18: 555-562.
53. Thomas AJ, Perry R, Kalaria RN, Oakley A, McMeekin W, et al. (2003) Neuropathological evidence for ischemia in the white matter of the dorsolateral prefrontal cortex in late-life depression. Int J Geriatr Psychiatry 18: 7-13.
54. Thomas AJ, Ferrier IN, Kalaria RN, Woodward SA, Ballard C, et al. (2000) Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. Am J Psychiatry 157: 1682-1684.
55. Gos T, Schroeter ML, Lessel W, Bernstein HG, Dobrowolny H, et al. (2013) S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. J Psychiatr Res 47: 1694-1699.
56. Falcone T, Fazio V, Lee C, Simon B, Franco K, et al. (2010) Serum S100B: a potential biomarker for suicidality in adolescents? PLoS ONE 5: e11089.
57. Schroeter ML, Abdul-Khaliq H, Sacher J, Steiner J, Blasig IE, et al. (2010) Mood disorders are glial disorders: evidence from in vivo studies. Cardiovasc Psychiatry Neurol 2010: 780645.
58. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE (2008) Serum markers support disease-specific glial pathology in major depression. J Affect Disord 111: 271-280.
59. Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, et al. (2003) S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 13: 235-239.
60. Rajkowska G, Stockmeier CA (2013) Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 14: 1225-1236.
61. Rajkowska G, Hughes J, Stockmeier CA, Javier Miguel-Hidalgo J, Maciag D (2013) Coverage of blood vessels by astrocytic endfeet is reduced in major depressive disorder. Biol Psychiatry 73: 613-621.
62. Uher T, Bob P (2012) Cerebrospinal fluid S100B levels reflect symptoms of depression in patients with non-inflammatory neurological disorders. Neurosci Lett 529: 139-143.
63. Zhang Y, Rothermundt M, Peters M, Wiesmann M, Hoy L, et al. (2009) S100B serum levels and word memory processing in remitted major depression as reflected by brain potentials. Neuropsychobiology 59: 172-177.
64. Yang K, Xie GR, Hu YQ, Mao FQ, Su LY (2008) The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression. J Neural Transm 115: 1687-1694.
65. Jang BS, Kim H, Lim SW, Jang KW, Kim DK (2008) Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response. Psychiatry Investig 5: 193-198.
66. Dietrich DE, Hauser U, Peters M, Zhang Y, Wiesmann M, et al. (2004) Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression. Neurosci Lett 354: 69-73.
67. Goncalves FM, Freitas AE, Peres TV, Rieger DK, Ben J, et al. (2013) Vatairea macrocarpa lectin (VML) induces depressive-like behavior and expression of neuroinflammatory markers in mice. Neurochem Res 38: 2375-2384.
68. Luo KR, Hong CJ, Liou YJ, Hou SJ, Huang YH, et al. (2010) Differential regulation of neurotrophin S100B and BDNF in two rat models of depression. Prog Neuropsychopharmacol Biol Psychiatry 34: 1433-1439.
69. Ye Y, Wang G, Wang H, Wang X (2011) Brain-derived neurotrophic factor (BDNF) infusion restored astrocytic plasticity in the hippocampus of a rat model of depression. Neurosci Lett 503: 15-19.
70. Veena J, Srikumar BN, Raju TR, Shankaranarayana Rao BS (2009) Exposure to enriched environment restores the survival and differentiation of new born cells in the hippocampus and ameliorates depressive symptoms in chronically stressed rats. Neurosci Lett 455: 178-182.
71. Rothermundt M, Arolt V, Wiesmann M, Missler U, Peters M, et al. (2001) S- 100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord 66: 89-93.
72. Bargerstock E, Puvenna V, Iffland P, Falcone T, Hossain M, et al. (2014) Is peripheral immunity regulated by blood-brain barrier permeability changes? PLoS ONE 9: e101477.
73. Mondello S, Müller U, Jeromin A, Streeter J, Hayes RL, et al. (2011) Bloodbased diagnostics of traumatic brain injuries. Expert Rev Mol Diagn 11: 65-78.
74. Shahim P, Tegner Y, Wilson DH, Randall J, Skillback T, et al. (2014) Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol 71: 684-692.
75. Ponath G, Schettler C, Kaestner F, Voigt B, Wentker D, et al. (2007) Autocrine S100B effects on astrocytes are mediated via RAGE. J Neuroimmunol 184: 214-222.
76. Beer C, Blacker D, Bynevelt M, Hankey GJ, Puddey IB (2010) Systemic markers of inflammation are independently associated with S100B concentration: results of an observational study in subjects with acute ischaemic stroke. J Neuroinflammation 7: 71.
77. Szelenyi A, Heukamp C, Seifert V, Marquardt G (2014) S100B, intraoperative neuromonitoring findings and their relation to clinical outcome in surgically treated intradural spinal lesions. Acta Neurochir (Wien) 156: 733-739.
78. Blennow K, Jonsson M, Andreasen N, Rosengren L, Wallin A, et al. (2011) No neurochemical evidence of brain injury after blast overpressure by repeated explosions or firing heavy weapons. Acta Neurol Scand 123: 245-251.
79. Derkach DN, Okamoto H, Takahashi S (2000) Neuronal and astroglial injuries in patients undergoing coronary artery bypass grafting and aortic arch replacement during hypothermic cardiopulmonary bypass. Anesth Analg 91: 1066-1072.
80. Kinoshita H, Iranami H, Fujii K, Yamazaki A, Shimogai M, et al. (2003) The use of bone cement induces an increase in serum astroglial S-100B protein in patients undergoing total knee arthroplasty. Anesth Analg 97: 1657-1660.
81. Reinsfelt B, Ricksten SE, Zetterberg H, Blennow K, Freden-Lindqvist J, et al. (2012) Cerebrospinal fluid markers of brain injury, inflammation, and bloodbrain barrier dysfunction in cardiac surgery. Ann Thorac Surg 94: 549-555.
82. Ashraf S, Bhattacharya K, Tian Y, Watterson K (1999) Cytokine and S100B levels in paediatric patients undergoing corrective cardiac surgery with or without total circulatory arrest. Eur J Cardiothorac Surg 16: 32-37.
83. Sellner J, Davies NW, Howard RS, Petzold A (2014) Neurofilament heavy chain as a marker of neuroaxonal pathology and prognosis in acute encephalitis. European Journal of Neurology 21: 845-850.
84. Skold MK, Risling M, Holmin S (2006) Inhibition of vascular endothelial growth factor receptor 2 activity in experimental brain contusions aggravates injury outcome and leads to early increased neuronal and glial degeneration. Eur J Neurosci 23: 21-34.
85. Shore PM, Thomas NJ, Clark RS, Adelson PD, Wisniewski SR, et al. (2004) Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: effect on biochemical markers. J Neurotrauma 21: 1113-1122.
86. Laskowitz DT, Grocott H, Hsia A, Copeland KR (1998) Serum markers of cerebral ischemia. J Stroke Cerebrovasc Dis 7: 234-241.
87. Kessler FH, Woody G, Portela LV, Tort AB, De Boni R, et al. (2007) Brain injury markers (S100B and NSE) in chronic cocaine dependents. Revista Brasileira de Psiquiatria 29: 134-139.
88. Marchi N, Angelov L, Masaryk T, Fazio V, Granata T, et al. (2007) Seizurepromoting effect of blood-brain barrier disruption. Epilepsia 48: 732-742.
89. Reiber H (1998) Cerebrospinal fluid-physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler 4: 99-107.
90. Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310: 173-186.
91. Marchi N, Fazio V, Cucullo L, Kight K, Masaryk T, et al. (2003) Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption. J Neurosci 23: 1949-1955.
92. Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, et al. (2003) Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci 21: 109-121.
93. Zongo D, Ribereau-Gayon R, Masson F, Laborey M, Contrand B, et al. (2012) S100-B protein as a screening tool for the early assessment of minor head injury. Ann Emerg Med 59: 209-218.
94. Johnsson P, Lundqvist C, Lindgren A, Ferencz I, Alling C, et al. (1995) Cerebral complications after cardiac surgery assessed by S-100 and NSE levels in blood. J Cardiothorac Vasc Anesth 9: 694-699.
95. Grocott HP, Arrowsmith JE (2001) Serum S100 protein as a marker of cerebral damage during cardiac surgery. Br J Anaesth 86: 289-290.
96. Bayram H, Hidiroglu M, Cetin L, Kucuker A, Iriz E, et al. (2013) Comparing S-100 beta protein levels and neurocognitive functions between patients undergoing on-pump and off-pump coronary artery bypass grafting. J Surg Res 182: 198-202.
97. Whitaker DC, Green AJ, Stygall J, Harrison MJ, Newman SP (2007) Evaluation of an alternative S100b assay for use in cardiac surgery: relationship with microemboli and neuropsychological outcome. Perfusion 22: 267-272.
98. Hernandez F, Jr., Brown JR, Likosky DS, Clough RA, Hess AL, et al. (2007) Neurocognitive outcomes of off-pump versus on-pump coronary artery bypass: a prospective randomized controlled trial. Ann Thorac Surg 84: 1897-1903.
99. Beck AT, Steer RA, Garbin MG (1988) Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 8: 77-100.
100. Tukey JW (1977) Exploratory data analysis. Reading, MA: Addison-Wesley.
101. Fazio V, Bhudia SK, Marchi N, Aumayr B, Janigro D (2004) Peripheral detection of S100beta during cardiothoracic surgery: what are we really measuring? Ann Thorac Surg 78: 46-52; discussion 52-43.
102. Jonsson H, Johnsson P, Alling C, Westaby S, Blomquist S (1998) Significance of serum S100 release after coronary artery bypass grafting. Ann Thorac Surg 65: 1639-1644.
103. Baufreton C, Allain P, Chevailler A, Etcharry-Bouyx F, Corbeau JJ, et al. (2005) Brain injury and neuropsychological outcome after coronary artery surgery are affected by complement activation. Ann Thorac Surg 79: 1597-1605.
104. Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, et al. (2010) Extracranial sources of S100B do not affect serum levels. PLoS ONE 5: e12691.